{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12"],"submitter":["She P"],"pubmed_abstract":["<i>Klebsiella pneumoniae</i> has emerged as a major clinical and public health threat owing to the increasing prevalence of healthcare-associated infections caused by multidrug-resistant or extensively drug-resistant strains. However, increasing antibiotic resistance and the absence of clinically effective antimicrobial agents make combination therapy an urgent need. This study investigated the anti-microbial activity of SPR741, a polymyxin B derivative, in combination with macrolide antibiotics (erythromycin and clarithromycin), against extensively drug-resistant and pandrug-resistant <i>K. pneumoniae.</i> Monotherapy, double, and triple combination therapies were performed to identify the most effective treatment combination using <i>in vitro</i> checkerboard, time-killing kinetics. Furt"],"journal":["Frontiers in cellular and infection microbiology"],"pagination":["858606"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8971605"],"repository":["biostudies-literature"],"pubmed_title":["SPR741, Double- or Triple-Combined With Erythromycin and Clarithromycin, Combats Drug-Resistant <i>Klebsiella pneumoniae</i>, Its Biofilms, and Persister Cells."],"pmcid":["PMC8971605"],"pubmed_authors":["Xu L","Liu Y","She P","Li Y","Li Z","Hussain Z","Liu S","Wu Y"],"additional_accession":[]},"is_claimable":false,"name":"SPR741, Double- or Triple-Combined With Erythromycin and Clarithromycin, Combats Drug-Resistant <i>Klebsiella pneumoniae</i>, Its Biofilms, and Persister Cells.","description":"<i>Klebsiella pneumoniae</i> has emerged as a major clinical and public health threat owing to the increasing prevalence of healthcare-associated infections caused by multidrug-resistant or extensively drug-resistant strains. However, increasing antibiotic resistance and the absence of clinically effective antimicrobial agents make combination therapy an urgent need. This study investigated the anti-microbial activity of SPR741, a polymyxin B derivative, in combination with macrolide antibiotics (erythromycin and clarithromycin), against extensively drug-resistant and pandrug-resistant <i>K. pneumoniae.</i> Monotherapy, double, and triple combination therapies were performed to identify the most effective treatment combination using <i>in vitro</i> checkerboard, time-killing kinetics. Furt","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-04T19:10:17.831Z","creation":"2025-04-04T19:10:17.831Z"},"accession":"S-EPMC8971605","cross_references":{"pubmed":["35372124"],"doi":["10.3389/fcimb.2022.858606"]}}